1379P - Clinico-biological characteristics of patients surviving more than two years with recurrent and/or metastatic (R/M) cancer: results of a transversa...

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Aetiology, Epidemiology, Screening and Prevention
Pathology/Molecular Biology
Basic Scientific Principles
Presenter Delphine Loirat
Citation Annals of Oncology (2014) 25 (suppl_4): iv481-iv485. 10.1093/annonc/mdu352
Authors D. Loirat1, C. Tlemsani2, F. Legouté3, C. Renaudin-Fonsegrive3, J. Arrondeau2, D. Lopez-Trabada3, M. Cabart3, M. Alt3, C. Helissey4, E. Boissier3, L. Verlingue3, E. Grignano3, A. Bellesoeur3, C. Le Tourneau5, B.J. Rousseau6
  • 1Oncology, Institut Curie, 75005 - Paris/FR
  • 2Medical Oncology, Hopital Cochin, AP-HP, 75014 - Paris/FR
  • 3Association Pour L’enseignement Et La Recherche Des Internes En Oncologie, AERIO, 75014 - Paris/FR
  • 4Oncology, HIA Val de Grace, 75005 - Paris/FR
  • 5Department Of Medical Oncology, Institut Curie, 75005 - Paris/FR
  • 6Pharmacology Unit, CHU Henri-Mondor, AP-HP, 94010 - Créteil/FR



R/M cancer patients may have prolonged survival, and R/M cancer can be considered as a chronic disease. To our knowledge, there are few data describing these patients. The main goal of the present study was to describe the clinico-biological features of patients surviving more than two years with R/M cancer.


During 4 months, we conducted a national multicentric survey about patients aged ≥ 18 with R/M cancer for more than 24 months. Clinico-biological data were collected in 39 French centers. Preliminary results of the first 200 patients are presented.


Most of them were women (70%) with breast cancer (44%) but a wide variety of other cancers were represented. Median age at diagnosis was 58 [range: 20-85]. Median time between primary tumor and R/M disease was 19 months [range: 0-312] with 39% of patients with a R/M disease at presentation. Median time from R/M disease was 46 months [range: 24-241]. At the time of R/M diagnosis, 72% of patients were not single; 48% were working while 37% were retired. At data collection, 88% of non-single patients were not separated, but only 32% of working patients were still working. At the time of R/M diagnosis, patients presented with good performance status (ECOG performance status of 0 or 1 in 88% of cases), without malnutrition (Body Mass Index <18.5 in only 4% of patients and mean albumin level of 36.8 g/L). 82% of patients had a local treatment of their primary tumor, 52% a local treatment for a metastasis. Mean number of treatment lines in advanced disease was 4.1 (1-13). 68% of patients were treated with at least one targeted therapy and 32.5% had been included in at least one clinical trial. 10% of patients only were followed by a palliative care team, 22% by a psychologist and 29.5% by a nutritionist.


Our preliminary results suggest that an important proportion of R/M cancer patients who live more than 2 years have been treated with a targeted therapy and have participated in a clinical trial. However, a majority of them have stopped their job and few of them received palliative care.


All authors have declared no conflicts of interest.